Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 7/20 | 0.38 |
| ▸ | JAK2 | O60674 | 6/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 3/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.36 |
| ▸ | TYK2 | P29597 | 5/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371889 | 0.76 | PI4KA (0.40) | GUSBPTGESJAK2GSK3BPI4KA | |
| SCHEMBL2372185 | 0.76 | PI4KA (0.61) | JAK2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2371959 | 0.76 | JAK2 (0.46) | GUSBPTGESJAK2GSK3BPI4KA | |
| SCHEMBL2372493 | 0.76 | TP53 (0.42) | GUSBPTGESJAK2GSK3BPI4KA | |
| SCHEMBL2372411 | 0.73 | GSK3B (0.53) | PTGESJAK2GSK3BTYK2 | |
| SCHEMBL2373081 | 0.72 | GSK3B (0.52) | PTGESJAK2GSK3BTYK2 | |
| SCHEMBL793590 | 0.71 | TYK2 (0.52) | JAK2TYK2 | |
| SCHEMBL2372642 | 0.71 | GSK3B (0.53) | JAK2GSK3BTYK2JAK1 | |
| SCHEMBL2371691 | 0.71 | GSK3B (0.51) | PTGESJAK2GSK3BTYK2 | |
| SCHEMBL14857938 | 0.70 | PI4KA (0.41) | GUSBPTGESJAK2GSK3BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2547338-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | GUSB 4531/4885PTGES 1438/4885JAK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.